Lakefront Biotherapeutics NV current report, Q1 FY2019

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV, a foreign private issuer, for the month of January 2019. The filing serves to incorporate by reference a press release dated January 4, 2019 (Exhibit 99.1). The registrant's principal executive office is located in Mechelen, Belgium. Note: The request metadata references "Lakefront Biotherapeutics NV," but the filing text explicitly identifies the registrant as Galapagos NV.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to distribute a press release and does not contain a financial statement or quantitative performance data.

Material Changes

The filing does not detail material financial changes versus prior periods. It references a press release issued on January 4, 2019, which is incorporated by reference, but the content of that press release is not included in the provided text.

Guidance, Outlook, and Risks

The filing text does not contain management commentary, guidance, outlook, or specific risk factors. It notes that the press release (Exhibit 99.1) contains quotes from Mr. Mark A. Steedman and Dr. Piet Wigerinck, but the substance of these quotes is not provided in the source text.

Investor Verification Checklist

  • Verify the content of the press release dated January 4, 2019 (Exhibit 99.1), as the filing itself only references it.
  • Confirm the specific nature of the announcement made by Galapagos NV on January 4, 2019, which is not detailed in this summary text.
  • Review the incorporated Registration Statements (Forms F-3 and S-8) for broader context on the company's capital structure and ongoing offerings.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.